A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40mg/0.4mL) and Prior SB5 (Adalimumab Biosimilar)

So-shin Ahn¹, Minkyung Lee¹, Yumin Baek¹, Sukho Lee¹

¹ Samsung Bioepis Co., Ltd., Incheon, Republic of Korea

Corresponding author

Name: So-shin Ahn, PhD
Address: Samsung Bioepis, Co., Ltd. 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, 21987, Korea
Phone number: +82-32-728-0376
email: soshin.ahn@samsung.com
Supplementary Table 1: VAS scores (mm) for pain at the injection site after treatment (Safety Set)

| Time points after injection |          | SB5-HC |          | SB5-LC |
|-----------------------------|----------|--------|----------|--------|
|                             |          | N = 94 | N = 94   |        |
| Before injection            | Mean ± SD| 0.2 ± 0.75 | 0.3 ± 0.67 |      |
|                             | Median (min-max) | 0.0 (0 - 6) | 0.0 (0 - 4) |      |
|                             | 75<sup>th</sup> percentile | 0.0 | 0.0 |      |
|                             | 90<sup>th</sup> percentile | 1.0 | 1.0 |      |
| Immediately after injection | Mean ± SD| 3.1 ± 4.98 | 9.2 ± 12.98 |      |
|                             | Median (min-max) | 1.0 (0 - 26) | 4.0 (0 - 61) |      |
|                             | 75<sup>th</sup> percentile | 3.0 | 12.0 |      |
|                             | 90<sup>th</sup> percentile | 9.0 | 23.0 |      |
| 15 minutes                  | Mean ± SD| 0.5 ± 1.34 | 1.7 ± 3.55 |      |
|                             | Median (min-max) | 0.0 (0 - 9) | 0.0 (0 - 25) |      |
|                             | 75<sup>th</sup> percentile | 1.0 | 2.0 |      |
|                             | 90<sup>th</sup> percentile | 1.0 | 5.0 |      |
| 24 hours                    | Mean ± SD| 0.1 ± 0.28 | 0.3 ± 0.76 |      |
|                             | Median (min-max) | 0.0 (0 - 1) | 0.0 (0 - 4) |      |
|                             | 75<sup>th</sup> percentile | 0.0 | 0.0 |      |
|                             | 90<sup>th</sup> percentile | 0.0 | 1.0 |      |
| 48 hours                    | Mean ± SD| 0.1 ± 0.38 | 0.2 ± 0.66 |      |
|                             | Median (min-max) | 0.0 (0 - 2) | 0.0 (0 - 4) |      |
|                             | 75<sup>th</sup> percentile | 0.0 | 0.0 |      |
|                             | 90<sup>th</sup> percentile | 1.0 | 1.0 |      |
| 96 hours                    | Mean ± SD| 0.1 ± 0.26 | 0.1 ± 0.28 |      |
|                             | Median (min-max) | 0.0 (0 - 1) | 0.0 (0 - 1) |      |
|                             | 75<sup>th</sup> percentile | 0.0 | 0.0 |      |
|                             | 90<sup>th</sup> percentile | 0.0 | 0.0 |      |

max = maximum; min = minimum; N = number of subjects in the safety set analysis; SB5-HC = 40 mg/0.4 mL SB5 in pre-filled syringe; SB5-LC = 40 mg/0.8 mL SB5 in pre-filled syringe; SD = standard deviation; VAS = visual analogue scales.
Supplementary Table 2: Summary of pharmacokinetic parameters by post-dose ADA status (PK Analysis Set)

| Parameter [unit] | ADA positive |          | ADA negative |          |
|------------------|--------------|----------|--------------|----------|
|                  | SB5-HC N = 93 | SB5-LC N = 94 | SB5-HC N = 93 | SB5-LC N = 94 |
| **AUC_{inf} [h·µg/mL]** | n = 87 | 2800.1 ± 1237.37 | 2990.7 ± 1126.3 | 4086.0 ± 853.17 | 4872.5 ± 1479.42 |
|                  | Mean ± SD     |          |              |          |
| **C_{max} [µg/mL]** | n = 87 | 4.300 ± 1.3903 | 4.332 ± 1.3434 | 4.205 ± 1.4513 | 4.354 ± 1.5174 |
|                  | Mean ± SD     |          |              |          |
| **AUC_{last} [h·µg/mL]** | n = 87 | 2437.7 ± 836.64 | 2566.4 ± 808.18 | 2925.9 ± 689.44 | 3472.9 ± 960.83 |
|                  | Mean ± SD     |          |              |          |
| **T_{max} [h]** | n = 87 | 142.733 (23.95-410.17) | 142.650 (24.02-336.45) | 130.825 (95.18-263.65) | 146.283 (118.92-214.80) |
|                  | Median (min-max) |        |              |          |
| **V_{z/F} [mL]** | n = 87 | 6620.9 ± 2587.60 | 6827.9 ± 2842.05 | 10923.4 ± 5243.75 | 9444.6 ± 3442.82 |
|                  | Mean ± SD     |          |              |          |
| **λ_{z} [1/h]** | n = 87 | 0.00312 ± 0.001863 | 0.00307 ± 0.002664 | 0.00113 ± 0.000682 | 0.00096 ± 0.000217 |
|                  | Mean ± SD     |          |              |          |
| **t_{1/2} [h]** | n = 87 | 331.71 ± 222.946 | 366.53 ± 229.402 | 738.01 ± 266.893 | 749.36 ± 168.422 |
|                  | Mean ± SD     |          |              |          |
| **CL/F [mL/h]** | n = 87 | 17.498 ± 8.8979 | 15.917 ± 8.0035 | 10.269 ± 2.7965 | 8.818 ± 2.5541 |
|                  | Mean ± SD     |          |              |          |
| **%AUC_{extrap} [%]** | n = 87 | 9.435 ± 9.9882 | 10.657 ± 10.1195 | 28.266 ± 11.7484 | 28.171 ± 5.8826 |

ADA = anti-drug antibody; AUC_{inf} = area under the concentration-time curve (AUC) from time zero to infinity; AUC_{last} = AUC from time zero to the last quantifiable concentration; CL/F = apparent total body clearance; C_{max} = maximum serum concentration; max = maximum; Mean = arithmetic mean; min = minimum; N = number of subjects in the PK analysis set; n = number of subjects who contributed to summary statistics; SB5-HC = 40 mg/0.4 mL SB5 in pre-filled syringe; SB5-LC = 40 mg/0.8 mL SB5 in pre-filled syringe; SD = standard deviation; t_{1/2} = terminal half-life; T_{max} = time to reach C_{max}; V_{z/F} = apparent volume of distribution during the terminal phase; λ_{z} = terminal rate constant; %AUC_{extrap} = percentage of AUC_{inf} due to extrapolation from time of last measurable concentration (T_{last}) to infinity. One subject in the SB5-HC group was excluded from the PK analysis set due to major protocol deviations. For one subject in the SB5-LC group only C_{max}, T_{max}, and AUC_{last} were included in the PK analysis as the regression slope could not be reliably estimated due to observations being below the lower limit of quantification during the elimination phase.